Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs QUALCOMM, Inc. (QCOM) Price & Performance

QUALCOMM, Inc.Trade

Price performance (Past 24H)

Key statistics

GSK plc vs QUALCOMM, Inc. — how do they compare? GSK plc trades at $46.87 (market cap $91.88B), while QUALCOMM, Inc. trades at $176.73 (market cap $187.95B). The key difference: QUALCOMM, Inc. is far larger — about 2× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and QUALCOMM, Inc. for 87 Days on average.

GSKQCOM
Market Cap
$91.88B$187.95B
Volume
7,730,5299,535,042
Sector
HealthTechnology
52-Week High
$61.18$251.10
52-Week Low
$43.24$124.07
Typical Hold Time
93 Days87 Days
Enterprise Value
$111.88B$194.92B
Dividend Yield
3.9%2.09%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.

The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.

QUALCOMM, Inc.

Qualcomm (QCOM) trades at $176.01, down 2.79% on the day, with a bearish technical signal but strong fundamentals including 21.01% net income margin and 33.75% ROE. Recent earnings show mixed results with Q2 2026 missing expectations, while the company benefits from diversification into AI data centers and automotive sectors. Analyst consensus price target stands at $204.48, representing 16% upside potential from current levels.

The stock presents a compelling opportunity with reasonable valuation (P/E 20.24) and transformative AI partnerships, particularly the Amazon AWS deal offering up to $60 billion in potential revenue. Key risks include smartphone market dependence and competitive pressures in AI chips. Wall Street sentiment leans positive with 43% buy ratings despite recent technical weakness.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GSK

No sentiment data available yet.

QCOM
54% Buy46% Sell
Avg holding period · 87 Days

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK →

About QUALCOMM, Inc.

Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.

Read more on QCOM →